UNSPSC 51282204: Cefmetazole

This classification denotes a cephalosporin antibiotic with the molecular formula C15H17N7O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J962UJT8H, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((cyanomethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-cis)- but generally known as cefmetazole, which bears US NIH Compound Identifier 42008.

UNSPSC 51282204 Cefmetazole is a Commodity code for a specific antibiotic pharmaceutical product, but the recent state and local procurement activity recorded under this code does not reflect purchases of cefmetazole itself. Instead, the tagged opportunities show state and local health agencies procuring other pharmaceutical products — antibiotic tablets (doxycycline and ciprofloxacin) through piggyback warehouse contracts, and naloxone with drug deactivation systems through direct competitive bidding. This mismatch between the code's nominal scope and actual procurement activity suggests either data-entry error in opportunity tagging or that cefmetazole is being purchased incidentally as part of larger pharmaceutical supply agreements rather than as a named line item. State and local health departments and counties appear to be the primary issuing bodies using this or related pharmaceutical codes, typically through cooperative purchasing vehicles (such as MMCAP Infuse consortia) or standalone competitive bids for emergency medical supplies.

Geographic activity includes Illinois and Florida in recent records. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract to Chartwell Rx LLC through MMCAP Infuse on August 28, 2026 (completed award, not an open solicitation), covering doxycycline and ciprofloxacin products with 12-month initial term and two optional renewal years. Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 drug deactivation systems annually, with quarterly deliveries and a response deadline of July 26, 2026. Neither opportunity explicitly names cefmetazole. If your firm supplies pharmaceutical products to state health departments or counties through cooperative agreements or direct bids, review current MMCAP Infuse and regional health-consortium contracts to identify whether cefmetazole is being requisitioned; the code itself shows limited targeted recent activity for the specific product.